Status of Peptides

FROM: Edwin Lee, M.D.

RE: Status of Peptides as of May 22, 2020

Although no harm or deaths have been reported due to peptides, the FDA issued a letter to Tailor Made Compounding to stop making certain peptides by April 23, 2020. The agency also prohibited the pharmacy from selling these peptides by May 15, 2020. The following peptides may no longer be compounded:

  • CJC1295/ Ipamorelin
  • BPC 157
  • LL-37
  • DSIP
  • Epitalon
  • Kisspeptin 10
  • ARA-290
  • MOTS-c
  • Dihexa
  • IGF-1
  • iRGD
  • Melanotan II
  • PNC-27
  • Aniracetam


Currently, other compounding pharmacies are still able to produce most of the peptides listed above.

The FDA will very likely send letters to other compounding pharmacies to stop the production of the banned peptides since these substances lack FDA approval, a monograph or inclusion on the 503A Bulk Drug Substance List. is a grassroots organization formed to preserve the use of peptides by requesting/lobbying for an open public meeting with the FDA to nominate the banned peptides to the 503A Bulk Drug Substance List. This group also wants to develop/get a monograph on each peptide.